Document Detail


Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial.
MedLine Citation:
PMID:  20876598     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: Continuous venovenous haemofiltration (CVVH) in the intensive care setting requires anticoagulation to prevent clotting of the extracorporeal circuit. Several protocols avoiding heparin and using regional citrate anticoagulation have been developed to diminish bleeding risks. However, data from randomized trials comparing citrate anticoagulation with systemic heparinization are very limited.
METHODS: One hundred and seventy-four patients on mechanical ventilation, requiring renal replacement therapy for acute renal failure, were included in this prospective randomized multicentre trial comparing regional citrate with systemic heparin. The study was performed at nine different intensive care units at university or academic teaching hospitals. The participants were randomized to either CVVH using regional citrate anticoagulation or CVVH using systemic anticoagulation with unfractionated heparin. The primary outcome was to compare treatment efficacy represented by the patients' acid base status on Day 3 and on each consecutive day. Several parameters of safety and efficacy were analysed as secondary outcomes.
RESULTS: Comparison of standard bicarbonate from Day 3 to Day 11 revealed no difference between both treatment modalities. Use of citrate resulted in less systemic anticoagulation, a lower risk of bleeding and a longer haemofilter patency. Episodes of hypercalcaemia, hypocalcaemia and the need for additional bicarbonate infusions occurred more often under citrate. The patients' high mortality was not influenced by the mode of anticoagulation.
CONCLUSIONS: Citrate may be used as a regional anticoagulant and the only buffering agent in CVVH with adequate treatment efficacy and safety. However, neither citrate nor heparin anticoagulation should be regarded as a therapeutic standard, since there is no advantage of one of these substances with regard to patient mortality.
Authors:
Gerd R Hetzel; Michael Schmitz; Heimo Wissing; Wolfgang Ries; Gabriele Schott; Peter J Heering; Frank Isgro; Andreas Kribben; Rainer Himmele; Bernd Grabensee; Lars C Rump
Related Documents :
18031098 - Hypereosinophilic syndromes.
2282348 - The effect of prolonged aspirin therapy on experimental balloon-catheter arterial wall ...
17634948 - A meta-analysis and systematic review of the efficacy and safety of anticoagulants as c...
19710438 - Malabsorption-associated warfarin resistance.
23206478 - Influence of different urination methods on the urinary systems of patients with spinal...
15302778 - Relationship between activated clotting time and ischemic or hemorrhagic complications:...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-27
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  26     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  232-9     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Medical Faculty, Heinrich-Heine University Düsseldorf, Germany. hetzel@uni-duesseldorf.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections
Comment In:
Nephrol Dial Transplant. 2011 Jan;26(1):9-11   [PMID:  21148029 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Management of acquired coagulopathy in acute paediatrics.
Next Document:  Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process?